Skip to main content

Remote Assessment of Disease and Relapse – Alzheimer’s Disease


Start Date
End Date
Total Funding
€ 7 640 145
Funding Programme

There is an urgent need for novel approaches assessing functional decline in early AD. The main goal of the RADAR-AD project is to develop a digital platform to detect subtle functional deficits in early Alzheimer’s disease (AD) individuals by integrating a meaningful combination of smartphone, wearable and/or home sensor based parameters. The system developed will be suitable for future longitudinal studies, including trials.

The objectives are to

1) Identify the most relevant functional domains and the most promising remote measurement tools (RMTs) for these domains based on reviewing the literature and piloting of RMTs in small studies;

2) Optimise the RADAR-CNS platform for use in AD studies;

3) Test the platform and selected RMTs in a real world environment clinical study with 240 participants across the AD spectrum ranging from the preclinical AD to the dementia stage;

4) Perform statistical modelling to estimate longitudinal predictions;

5) Discuss results with regulatory agencies in order to obtain guidance about how to develop a path for formal qualification as outcome measurements in future therapeutic interventions.

Considering the limited budget and project duration, we will rely upon already available technology platforms and on available longitudinal datasets where possible. The consortium includes experts in clinical dementia studies, computer science, bioinformatics, regulatory policies, ethics, and patient and public involvement (PPI). Additional strengths of the consortium are the deep and broad interface with RADAR-CNS and related IMI projects, and the access to large amount of patient-level data from key European cohort studies for modelling purposes.

Project partners

Ethniko Kentro Erevnas Kai Technologikis Anaptyxis
Stichting Lygature
Software Ag
Fraunhofer Gesellschaft Zur Foerderung Der Angewandten Forschung E.V.
Novartis Pharma Ag
The Hyve Bv
Takeda Development Centre Europe Ltd
Stichting Vumc
Karolinska Institutet
Agentschap College Ter Beoordeling Van Geneesmiddelen
The Chancellor
Masters And Scholars Of The University Of Oxford
Eli Lilly And Company Limited
Alzheimer Europe
Altoida Ag
Janssen Pharmaceutica Nv
King'S College London

Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).